Nozomi Miyake
Okayama, 7008558, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
CLEIA-based type IV collagen 7S for second-step assessment of MRE-defined clinically significant fibrosis in MASLD with indeterminate FIB-4.
Journal: Scientific reports
Published: May 06, 2026
Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.
Journal: JHEP reports : innovation in hepatology
Published: March 27, 2026
High Intrahepatic cccDNA in Resolved HBV Infection: Insights From Living Donor Liver Transplantation With Anti-HBc-Positive Grafts.
Journal: Journal of gastroenterology and hepatology
Published: December 20, 2025
Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: November 07, 2025
Cholecystectomy Is Linked to Worse Clinical Outcomes in Primary Sclerosing Cholangitis.
Journal: Cureus
Published: March 06, 2025
Clinical Variables That Predict Liver-related Events in Steatotic Liver Disease Diagnosed by a Liver Biopsy.
Journal: Internal medicine (Tokyo, Japan)
Published: February 09, 2025
CRISPR-mediated proximity labeling unveils ABHD14B as a host factor to regulate HBV cccDNA transcriptional activity.
Journal: Hepatology communications
Published: September 19, 2024
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 21, 2024
A smartphone app-based intervention combined with face-to-face sessions for alcohol dependence at internal medicine clinics: A randomized controlled trial.
Journal: General hospital psychiatry
Published: February 12, 2024
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: August 17, 2023
Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA.
Journal: Hepatology communications
Published: July 04, 2023
Last Updated: 09/26/2026